Cantor Fitzgerald Reiterates Overweight on CymaBay Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on CymaBay Therapeutics (NASDAQ:CBAY) and maintained a $15 price target.
August 31, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on CymaBay Therapeutics and maintained a $15 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for CymaBay Therapeutics. The maintained price target of $15 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100